Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00001237 · ClinicalTrials.gov registry record · Phase 2
Pilot Protocol for the Treatment of Patients With Small Non-Cleaved and Diffuse Large Cell Lymphomas
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
NCT00001237: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00001237 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 120 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00001237, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
Study Summary
Major improvements in the treatment of childhood non-lymphoblastic lymphomas have taken place in the last ten years. Though the survival rate in low risk patients (i.e., those with stage I \& II disease and serum LDH of less than 350 IU/dL) was as high as 90% with the previous Pediatric Branch protocol, only 32% of patients in the high risk group achieved long term remission. The present protocol is designed to improve survival in the high risk group by using alternating non-cross resistant drug regimens. We plan to determine whether using granulocyte-macrophage colony stimulating factor (GM-CSF) in this group would increase dose-intensity and ameliorate myelotoxicity. We also plan to study the effect on survival of decreasing the duration of treatment to three months from the present year-long therapy in low-risk patients.
Interventions
- DRUG granulocyte-macrophage colony stimulating factor (GM-CSF)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 1989-03 |
| Est. Completion | 2000-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00001237
The ClinicalTrials.gov registry entry for NCT00001237 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which granulocyte-macrophage colony stimulating factor (GM-CSF) is the first listed.
NCT00001237 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00001237 about?
NCT00001237 is a clinical study titled "Pilot Protocol for the Treatment of Patients With Small Non-Cleaved and Diffuse Large Cell Lymphomas". Major improvements in the treatment of childhood non-lymphoblastic lymphomas have taken place in the last ten years. Though the survival rate in low risk patients (i.e., those with stage I \& II disease and serum LDH of less than 350 IU/dL) was as high as 90% with the previous Pediatric Branch proto...
What is the current status of trial NCT00001237?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 1989-03. Estimated completion is 2000-04.
What interventions are being tested in trial NCT00001237?
The interventions under investigation include: granulocyte-macrophage colony stimulating factor (GM-CSF) (DRUG).
Who is sponsoring clinical trial NCT00001237?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.